Evidence map›Paper›PMID 38872134›Full record

ArticleBMC nephrology2024

A case of TAFRO syndrome after vaccination, successfully treated with cyclosporine.

Yasuyuki Mimura, Katsuhito Kojima, Arisa Fujikawa, Shioko Okada, Akira Fujimori, Akihiro Kuma, Takahiro Kuragano

Abstract readCase Reports
In one paragraph

Article in BMC nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yasuyuki MimuraDepartment of Cardiovascular and Renal Medicine, Hyogo Medical University, 1-1 Mukogawa-Cho, Nishinomiya, Hyogo, 663-8501, Japan. ya-mimura@hyo-med.ac.jp.
Katsuhito KojimaDepartment of Nephrology, Konan Medical Center, 1-5-16 Kamokogahara, Higashinada-Ku, Kobe, Hyogo, 658-0064, Japan.
Arisa FujikawaDepartment of Nephrology, Konan Medical Center, 1-5-16 Kamokogahara, Higashinada-Ku, Kobe, Hyogo, 658-0064, Japan.
Shioko OkadaDepartment of Nephrology, Konan Medical Center, 1-5-16 Kamokogahara, Higashinada-Ku, Kobe, Hyogo, 658-0064, Japan.
Akira FujimoriDepartment of Nephrology, Konan Medical Center, 1-5-16 Kamokogahara, Higashinada-Ku, Kobe, Hyogo, 658-0064, Japan.
Akihiro KumaDepartment of Cardiovascular and Renal Medicine, Hyogo Medical University, 1-1 Mukogawa-Cho, Nishinomiya, Hyogo, 663-8501, Japan.
Takahiro KuraganoDepartment of Cardiovascular and Renal Medicine, Hyogo Medical University, 1-1 Mukogawa-Cho, Nishinomiya, Hyogo, 663-8501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTAFRO syndrome is a rare disorder that causes thrombocytopenia, generalized oedema, fever, organ enlargement, and renal impairment. Few reports have suggested an association with vaccines, and few cases have undergone renal biopsy. TAFRO syndrome is often severe and fatal, and its cause is unknown. We report a case of TAFRO syndrome that occurred after vaccination with the coronavirus disease 2019 (COVID-19) vaccine. CASE PRESENTATION: An 82-year-old woman received two doses of the BNT162b2 mRNA vaccine 3 weeks apart. Two weeks later, she was admitted to the hospital with oedema, accompanied with renal failure and thrombocytopenia. After close examination, she was diagnosed with TAFRO syndrome. She was treated with steroids, cyclosporine, and thrombopoietin receptor agonists. The patient was discharged after several months in remission.

conclusionsAlthough an incident of TAFRO syndrome after COVID-19 vaccination has been previously reported, this is a rare case in which the patient went into remission and was discharged. A renal biopsy was also performed in this case, which was consistent with previous reports. The favorable treatment course for TAFRO syndrome provides valuable insights.

Indexed as

CyclosporineAged, 80 and overBNT162 VaccineCOVID-19COVID-19 VaccinesEdemaFemaleHumansImmunosuppressive AgentsThrombocytopeniaBNT162 VaccineCOVID-19 VaccinesCyclosporineImmunosuppressive AgentsBNT162b2 mRNACOVID-19ITP (idiopathic thrombocytopenic purpura)MIS-A (multisystem inflammatory syndrome in adults)SCLS (systemic capillary leak syndrome)TAFRO syndrome

Identifiers

PMID38872134
PMCPMC11177486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.